We have located links that may give you full text access.
Treatment of locally recurrent carcinoma of the nasopharynx.
Radiology 1975 November
Forty-two patients with recurrent nasopharyngeal carcinoma in the primary site and/or neck nodes were treated at the University of California, San Francisco, between 1940 and 1974. Sixty-nine per cent of the recurrences appeared within 3 years and 83% within 5 years after initial treatment. Retreatment included external radiotherapy and/or intercavitary radium or cobalt beads in the majority of cases. The actuarial survival rate was 41% at 5 years after first recurrence. Survival rates increased proportionally with increasing time between initial treatment and recurrence. There was no statistically significant difference in survival rates with respect to age, sex, race, or histology. Local soft-tissue or bone necrosis developed in 9 patients, but both conditions were tolerated well.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app